These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
84 related articles for article (PubMed ID: 9815991)
1. Effect of sublethal liver injury on doxorubicin metabolism. August DA; Halter S; Brenner DE Clin Cancer Res; 1995 Mar; 1(3):351-8. PubMed ID: 9815991 [TBL] [Abstract][Full Text] [Related]
2. Effect of allyl alcohol-induced sublethal hepatic damage upon doxorubicin metabolism and toxicity in the rabbit. Brenner DE; Anthony LB; Halter S; Harris NL; Collins JC; Hande KR Cancer Res; 1987 Jun; 47(12):3259-65. PubMed ID: 3581067 [TBL] [Abstract][Full Text] [Related]
3. New aspects in probucol cardioprotection against doxorubicin-induced cardiotoxicity. El-Demerdash E; Ali AA; Sayed-Ahmed MM; Osman AM Cancer Chemother Pharmacol; 2003 Nov; 52(5):411-6. PubMed ID: 12879278 [TBL] [Abstract][Full Text] [Related]
4. Doxorubicin pharmacokinetics in the rabbit. Maniez-Devos DM; Baurain R; Trouet A; Lesne M J Pharmacol; 1985; 16(2):159-69. PubMed ID: 4058012 [TBL] [Abstract][Full Text] [Related]
5. Investigation of the influence of modulation of P-glycoprotein by a multiple dosing regimen of tamoxifen on the pharmacokinetics and toxicodynamics of doxorubicin. Darvari R; Boroujerdi M Cancer Chemother Pharmacol; 2005 Nov; 56(5):497-509. PubMed ID: 15937726 [TBL] [Abstract][Full Text] [Related]
6. Impact of endotoxin-induced changes in P-glycoprotein expression on disposition of doxorubicin in mice. Hartmann G; Vassileva V; Piquette-Miller M Drug Metab Dispos; 2005 Jun; 33(6):820-8. PubMed ID: 15778272 [TBL] [Abstract][Full Text] [Related]
7. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies). National Toxicology Program Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289 [TBL] [Abstract][Full Text] [Related]
8. NTP Toxicology and Carcinogenesis Studies of Oxazepam (CAS No. 604-75-1) in Swiss-Webster and B6C3F1 Mice (Feed Studies). National Toxicology Program Natl Toxicol Program Tech Rep Ser; 1993 Aug; 443():1-321. PubMed ID: 12595920 [TBL] [Abstract][Full Text] [Related]
9. Doxorubicin and daunorubicin plasmatic, hepatic and renal disposition in the rabbit with or without enterohepatic circulation. Maniez-Devos DM; Baurain R; Lesne M; Trouet A J Pharmacol; 1986; 17(1):1-13. PubMed ID: 3713196 [TBL] [Abstract][Full Text] [Related]
10. Effect of tamoxifen pretreatment on the pharmacokinetics, metabolism and cardiotoxicity of doxorubicin in female rats. Vaidyanathan S; Boroujerdi M Cancer Chemother Pharmacol; 2000; 46(3):185-92. PubMed ID: 11021735 [TBL] [Abstract][Full Text] [Related]
11. Cardiotoxicity of doxorubicin/paclitaxel combination in rats: effect of sequence and timing of administration. Saad SY; Najjar TA; Alashari M J Biochem Mol Toxicol; 2004; 18(2):78-86. PubMed ID: 15122649 [TBL] [Abstract][Full Text] [Related]
12. NTP Toxicology and Carcinogenesis Studies of Pentachloroanisole (CAS No. 1825-21-4) in F344 Rats and B6C3F1 Mice (Feed Studies). National Toxicology Program Natl Toxicol Program Tech Rep Ser; 1993 Apr; 414():1-284. PubMed ID: 12616284 [TBL] [Abstract][Full Text] [Related]
13. A novel doxorubicin-glucuronide prodrug DOX-GA3 for tumour-selective chemotherapy: distribution and efficacy in experimental human ovarian cancer. Houba PH; Boven E; van der Meulen-Muileman IH; Leenders RG; Scheeren JW; Pinedo HM; Haisma HJ Br J Cancer; 2001 Feb; 84(4):550-7. PubMed ID: 11207053 [TBL] [Abstract][Full Text] [Related]
14. New intra-arterial drug delivery system for the treatment of liver cancer: preclinical assessment in a rabbit model of liver cancer. Hong K; Khwaja A; Liapi E; Torbenson MS; Georgiades CS; Geschwind JF Clin Cancer Res; 2006 Apr; 12(8):2563-7. PubMed ID: 16638866 [TBL] [Abstract][Full Text] [Related]
15. The antiproliferative drug doxorubicin inhibits liver fibrosis in bile duct-ligated rats and can be selectively delivered to hepatic stellate cells in vivo. Greupink R; Bakker HI; Bouma W; Reker-Smit C; Meijer DK; Beljaars L; Poelstra K J Pharmacol Exp Ther; 2006 May; 317(2):514-21. PubMed ID: 16439617 [TBL] [Abstract][Full Text] [Related]
16. Metallothionein acts as a cytoprotectant against doxorubicin toxicity. Kimura T; Fujita I; Itoh N; Muto N; Nakanishi T; Takahashi K; Azuma J; Tanaka K J Pharmacol Exp Ther; 2000 Jan; 292(1):299-302. PubMed ID: 10604962 [TBL] [Abstract][Full Text] [Related]
17. Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin. Lopes de Menezes DE; Hudon N; McIntosh N; Mayer LD Clin Cancer Res; 2000 Jul; 6(7):2891-902. PubMed ID: 10914739 [TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of intravenously administered stealth liposomal doxorubicin modulated with verapamil in rats. Wang JC; Liu XY; Lu WL; Chang A; Zhang Q; Goh BC; Lee HS Eur J Pharm Biopharm; 2006 Jan; 62(1):44-51. PubMed ID: 16126379 [TBL] [Abstract][Full Text] [Related]
19. The influence of the time interval between monoHER and doxorubicin administration on the protection against doxorubicin-induced cardiotoxicity in mice. Bruynzeel AM; Mul PP; Berkhof J; Bast A; Niessen HW; van der Vijgh WJ Cancer Chemother Pharmacol; 2006 Nov; 58(5):699-702. PubMed ID: 16565833 [TBL] [Abstract][Full Text] [Related]
20. Effect of dexrazoxane on doxorubicin pharmacokinetics in young and old rats. Cusack BJ; Musser B; Gambliel H; Hadjokas NE; Olson RD Cancer Chemother Pharmacol; 2003 Feb; 51(2):139-46. PubMed ID: 12647015 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]